we'll talk about the blockbuster biogen samsung report. speak with rent the runway co-founder jenny fleiss about the opportunities for retailers in the metaverse and we'll look at the billions of dollars flowing into esg funds and whether the esg scores given to companies actually make a difference and mean anything that's all coming in the second hour but first of all, we have just six minutes left in the trading day. mike santoli, and we've got jason from odyssey capital advisers mike, a very nice rally into the close. >> yeah. obviously it's a bit of a drift as opposed to a stampede but racking up the score in a year and a month already being won by the bulls, also still a little bit on the more defensive laggard side a lot of pharma and staples in the leaders today. but obviously also still a pretty firm tone, a lot of selling got done in november into december. that's for sure. >> jason, do you make much of these end-of-year moves? and how are you set up for 2022? >> good to see you happy holidays so for us i think looking at the mark

. >> tonight on "fast," biogen and what it means for investors and who could be next. and plus going bargain hunting five stocks down double-digits, will they be the comeback kids of 2022 and find out on trade it or fade it and out with the new and in with the old. best bets in fin tech. welcome to "fast money," i'm melissa lee. tonight's lineup guy adami will join us in moments. we start out with another record day on wall street closing at fresh all-time highs for those of you keeping track at home, that is a 70th record close for the s&p just this year with stocks hitting all-time highs we want to know what is a setup going into next year we tasked each of our traders could come up with their most important charts into the market heading into 2020. so let's get right to it pete, what is your chart >> well i'm going to go with wti, crude oil in other words. and the reason i say that, mel, it was left for dead at one point in time. it really was. it traded in negative. but when you look at this and all of the different implications that it actually has on the marks th

biogen shares surged 13% on the reports from the korean economic daily. a company representative says it does not comment on market moves and speculation. a record slump in performance. the recent drawdown caused in part by high flier asset management. it is the latest headwind for china's quan hedge fund. -- quant hedge fund as popular traits become increasingly crowded. a jury found ghislaine maxwell guilty of lowering and grooming underage girls for sexual abuse by jeffrey epstein. the verdict came after five days of deliberation. maxwell has been convicted on five of the six charges including sex trafficking of the minor which carries a possible prison sentence of up to 40 years. president biden plans to talk with the vladimir putin thursday as the u.s. and allies raise alarm about russia's troop buildup on the ukraine border. the u.s. president warned that russian aggression would be met with unprecedented economic penalties. russia's leader denies plans for a military occupation warning nato against stationing sensitive weapons in ukraine. korea and

jim o'neil weighing in on that and the risks to global growth >>> and later, biogen throwing cold water on what could have been a massive m&a deal. it's thursday, december 30th, 2021, you're watching "worldwide exchange" here on cnbc >>> good morning, i'm seema mody in for brian sullivan at this hour great ton with you today here's how stock futures are looking on this thursday morning. this after the s&p 500 posted the 70th record close of the year nasdaq higher by 45, dow jones up 25 points yesterday was trailing 1995 when it saw 77 record closes in a single year. according to cnbc's robert hum with 70 record closes over the course of 2021's 250 trading days that means the s&p has recorded a record close 28% of the time, that's a pace of every four days. a quick sector check that tells you where we're seeing the gains, health care, real estate, materials, consumer staples and utilities. and we continue to watch the story in oil remember, for the year, energy is the best performing sector right now oil getting back some of the gains, wti down about .6%, at $76. and crypto currencies ha

overnight samsung denying a report it's in talks to buy biogen shares of biogen jumped more than 9% on the initial report from a korean newspaper that said a deal could value biogen at $42 billion that's about a 20% premium from its current price or the price it was before you saw the big jump the company makes treatments for neurological conditions, obviously it's been in the news a lot this year for alzheimer's, the drug that was kind of controversial that's been approved for use at this point when i first saw this, i scratched my head, what would samsung be doing with this, but samsung buy lodgics is the unit reportedly going through with the deal samsung talked about how it has a lot of money to invest, something north of $200 billion over the next three years in areas like artificial intelligence and bio technology. >> when it first crossed you were thinking samsung galaxy biogen >> exactly. >> i was thinking the health care unit was more medical devices which it is slightly bigger by revenue but they're a goliath and have been loosely linked in this area before, specifically to b

john in illinois, i'm looking to add healthcare to my portfolio would you recommend biogen or zimmer >> i would recommend devices but rather than zimmer, i would recommend striker. they're able to continue to grow their share and scale in this market they outperformed zimmer and smith and nephew for 2021 and i expect that to continue. zimmer could get more ambitious on pricing, but i still think stryker and the medical device space. >> it's at an all-time high today and up huge this year. >> both reopening trades healthcare reopening has not been talked a lot on this show, but both reopening trades and could continue as procedure volumes increase >> all right joe. >> well, scott, we own thermofisher and it's playing to the theme biogen and zimmer. you're coatching a falling knif and not buying a quality balance sheet. i would suggest you want to buy these stocks when they give you multiple quarters. it doesn't mean that i don't like healthcare, equipment makers and i don't like the pharmaceuticals and i don't like the biotech in large cap, but i think there's better places to go and

biogen shares.med sources that biogen approached samsung about a potential takeover. samsung group, we should point out. i think we have a response from biogen. kriti: up just shy of 10%. this is coming on the back of a pretty steep hit. putting all their eggs in the basket of that controversial all cymer's treatment that was rejected in japan and europe. romaine: biogen is saying the company does not comment on market rumors and speculation. this is just based on one report citing unnamed sources. biogen not willing to touch this at least publicly. nonetheless, shares are up about 9% on the day. the stock has underperformed pretty significantly over the last several months. you are listening to a global simulcast on bloomberg tv, radio, and youtube. romaine: this is bloomberg markets. special coverage all week long, global simulcast of bloomberg tv, radio, and youtube. we welcome our out inches across all plot forms. basically a sideways day for the s&p 500. the dad trading at a record high as far

could use some support that samsung is denying the report at biogen is down.son & johnson. good news on their booster? it protect against omicron. lauren: they found two doses of the regular j and j shot and number 2 of the booster offers 85% protection from hospitalization from omicron. that good news were vaccine that has been dogged for being less effective than pfizer and moderna. this study found the j&j works as well as a booster for people who got two pfizer shots. you can get pfizer the first round and then get j&j as your booster. that is effective for the south african study. you can mix and match. ashley: that is good news, mix and match indeed. let's get to the airlines, jetblue. the surge in covid causing the airline to delay thousands of flights was the question is how far out? lauren: mid january. they are cutting 1200 flights from today through january 13th. they want to avoid sick outs that caused them to have last-minute cancellations. this suggests they are trying to get ahead of a further rising cases because of new year's so it seems like

. ♪ cheryl: your morning mover today, it is biogen.aking a look at the storks it is under pressure, down 6% an change, the stock losing ground after a south korean firm denied reports it was in talks to buy the u.s. drug maker. according to korea economic daily, biogen you approached samsung biologics to buy its stock valued at more than $42 billion. biogen which makes drugs for neurological diseases currently has more than 30 new drugs in its pipeline but still that is a big mover today on this thursday morning. well, getting back to the broader markets for all of you, futures really we've got another green start, another kickoff. we've been talking about the santa claus rally. looks like it's still going. i don't want to jinks anything. the dow and s&p 500 bows closed as new records yesterday, the 70th record close for the s&p this year. we have weekly jobless claims coming out this morning at 8:30 a.m. that could be a market moving report. we'll bring that to you live when it crosses. i do want to bring in cornerstone wealth managin

>> governments around the world are vetoing it, biogen is in trouble, but people on the panel all votedfer saying the people at -- to run the country. >>> france has canceled its order for the merck antiviral, hoping to received, instead, the pfizer drug before the end of january. jim, talking about levels, looking at trader positioning, wondering how long that can last it sounded like you were conditioning viewers to maybe look on the lookout for 10%, 14% correction early next year. >> i think we can spike here one of the my favorite commodity analysts, carly garner said, look, this is an unsustainable advance from the bottom in 2020. there's never been anything like it i just want people to understand, we're in rarefied territory. we've been going up and up and up, and garner's word said basically it's not historically been sustainable i believe in the santa rally, but then my crystal ball does get clouded if we got, say, the pfizer pill but i think we are a bit glib about what could happen with omicron dr. topol saying if -- just go back to the old days it's going to be another reall

>>> we want to bring your attention to shares of biogen surging on report that samsung in negotiations to buy the drug maker in a deal world worth $42 billion. we have reached out to both companies. we will bring you updates as soon as we get them. >>> still to come here on "power lunch," tesla. no company has been able to touch their ev cars or batteries? we will hear from the newest contender. >>> we will also get a check on the market as the dow tries for a sixth straight ssi oesonf gains. "power lunch" will be right back want it all. you have to deal with higher expectations and you have to lower wait times. with ibm, you can do both. your business can unify apps and data across your clouds. so you can address supply chain issues in real time, before they impact your bottom line. predicting and managing operational issues that's why so many businesses work with ibm. small businesses like yours make gift-giving possible. now, comcast business has an exclusive gift for you. introducing the gift of savings sale. for a limited time, ask how to get a great deal for your business. and ge

biogen shares are tanking after samsung denied a korean media report that the u.s.n talks to sell itself to the company. the report sent biogen shares soaring nearly 10% today but if you take a look now they are down more than 7%. moving over to the airlines, jet blue says it will cut nearly 1,300 flights from its schedule through january 13, as it deals with an outbreak of covid-19 infections among its staff. the airline is based in new york , where the number of covid cases are striking dramatically. united airlines announced they would also be cutting back on flights due to the virus. you can see here on the board the airline stocks are mixed but just focusing on jetblue down just a little under a half a percent at the moment. >> richard branson's satellite company virgin orbit kicked off trading on the nasdaq today following a spac merger, with blank check company next gen acquisition corp. trading under the ticker vorb, virgin orbit is branson's second space company to hit the stock market and is a spin-off of virgin galactic which went public in 2019. the comp

the medicine, made by biogen, it's already faced a lot of controversy.this drug for use in the united states back in june, but even then the medical community was divided about whether the data shows the drug actually works. today the european medicines agency announced the drug does not appear to be effective at treating adults with early stage alzheimer's. the regulator says that the studies also raised concerns about the medicine's safety. they say brain scans of patients suggested abnormal swelling or bleeding essentially, the agency determined that the risks of this alzheimer's drug do not outweigh the benefits. officials at biogen say they plan to ask the eu panel to re-examine its decision. >>> first came black friday. then it was cyber monday now bring on super saturday. the countdown to christmas continues. and even though a lot of people shopped and shipped early, retailers are still expecting a lot of action. >>> james bond wasn't able to save the box office. so how about spider-man? the friendly neighborhood superhero swinging into thears but

biogen is in talks for selling off to samsung. this is bloomberg. ♪ ♪ >> this is my kitchen table and my filing system. over the past three decades, i have been an investor. at the highest calling of mankind i thought was private equity and then, i started interviewing. i watch her interview. i learned from doing my interviews how leaders make it to the top. i asked him how much he wanted. he said $250,000. i did no due diligence. how they stay there. you don't feel in aquatic -- inadequate because you're the second wealthiest man now, right? one of the most successful entrepreneurs in silicon valley is reid hoffman. he helped build paypal and started linkedin. he has been an early investor in facebook and airbnb and is a partner in one of the leading venture firms in silicon valley. i had to find out what it takes to be a great entrepreneur in my conversation with him. the venture capital world seems a can never get better. everybody is making money. values are high but returns are high. can they get better than this? are you wor

the shutdown -- biogen jumped after a report saying it is in talks to sell to samsung. the gain was the most since the alzheimer's treatment was approved under the u.s. on a junior pick -- in june. we will be watching samsung. we have november industrial output figures for south korea up 5.5% year-over-year, better then the estimate 4.4% growth. increased auto and chip production is credited. it will be november -- that was before november and the latest round of closure than lockdowns. nikkei futures open after yesterday's .6% drop, just below 115. this is bloomberg. >> why didn't you get a bigger book? >> this is the constitution and it is smaller. >> all right. >> a lot as justices of the supreme court carry around the constitutional time. is that because you will forget what is in it or you just read it over and over again? >> you never never know when somebody will ask you a question. somebody says, what does article three section 19 say? they expect you to know. you have it here. there it is. >> so, your book, this book is an interesting book in the sense that it

the drug with biogen did not get backing. we will keep an eye on that. yen, as well.but well above one 14 point 12. talking about sony financials, 11420 being aligned line in the sand. moving to south korea. the south korean kospi also showing gains. up .5%. once again, we will have to keep an eye on volume. stronger korean won versus the u.s. dollar, by about .3%. flows to the end of the year likely to be a bit volatile. haidi: we are seeing three days of gains in sydney. really a lot of traders would have gone off for the holidays, but the volume we see at the moment, we see strong gains. particularly with health care and financials. up .3%. we also continue seeing resilience when it comes to these risk commodities. aussie and kiwi dollars holding. fueled by bouts in stocks and commodities, and broader risk on sentiment. the aussie had enclosed -- having closed that. we are seeing modest gains off of the session highs for kiwi stocks in new zealand. vonnie: new studies show omicron may be less likely to send patients to hospital than delta. it comes as a new pfizer

sliding that move after samsung denied a report that it was in talks to buy biogen and combine it.cals dropped after a jury found that they fueled opioid abuse in new york. wilfred? >>> mike, let's get to mike santoli for a closer look at the jobless claims data. mike >> yeah. you guys were talking with jared bernstein earlier about the big drop in initial claims if you look at the chart of continuing claims, a twin part of the report, it shows you just about back to prepandemic levels we're just above 1.7 million excellent trend. shows you a good degree of healing until job market and consumers in theory are in a good spot finding jobs and because of the some what of a cushion from the stimulus to spend and service debt that's a good macro input. look at the consumer finance companies with a run higher in this year and really all down kind of double digits or more from the highs capital one, discover financial. so clearly loss rates are not going to get better. it is interesting. these are some of the cheapest stocks in the market trading at four to five times earnings it's obviou

company the stock giving up most of yesterday's gains after the initial report said deal could value biogenroger getting a boost with the company's board of directors approving a $1 billion stock buyback plan that name up more than 40% year to date, up about 1% right now and a dip for chip giant micron, warning that a covid lockdown in the chinese city of xian would impact production. samsung issuing a similar warning. scott? >> leslie, the dow thihitting another record high as we close out years. for more on the markets let's bring in harris associates partner, cio of international equity, david herro, nice to see you again. >> good morning. thanks for having me on the show today. >> yeah. we appreciate you being here we're talking about ending the year so strongly, why should i think about investing internationally when right here, right now looks pretty good? >> for that reason you've seen a strong uptake in u.s. stock prices and valuations, and what has basically been ignored is what's happening in the overseas markets, in the european markets and to some degree even some of the chinese

third lump of coal, i don't like what biogen has done with the alzheimer's drug and the fda went against the panel of doctors who actually analyzed the things. alzheimer's is worse i'm putting my money on eli lilly. their drug comes up for fda approval next year while we're hitting the shame. can i say that mo, larry, curley are the cdc, fda and the nih even when they're right they're doing damage they have divg messages or no messages some shoot from the hip, others say nothing. i know the biden administration wanted to defer to the scientists but they've taken that way too far finally, let's not forget about att wrecked by management. company destroyed one of the most pristine balance sheets in the industry it had to cut the one thing investors wanted from the company, shameless just shameless bottom line, look, i don't want to be a grinch 'tis the season to be jolly so let's just say that with the averages up nicely it's certain that santa claus has been hanging around town. let's take some questions. let's go to steve in california. steve. >> caller: boo-yah, jim, and major props for

a key european authority has issued a key negative opinion on biogen's controversial treatment for alzheimer's disease. in june, the u.s. regulators approved the results. i'm leigh-ann gerrans. this is bloomberg. ♪ ♪ >> there could be hopefully the last phase of the pandemic turning to an endemic that we could then manage on a seasonal basis with the technology we have. we are not seeing it in our bookings in a material way. some international, yes. but it is something that i think come over time, we will look back and it was another step to get healthy. tom: i will not mince words. in my pandemic travel, the best service has been mr. bastian's fortress, delta of atlanta. trying to manage the message for all of us into the holiday season. jonathan ferro on sabbatical. caroline hyde in a beleaguered london. helane becker, our senior research analyst at cowen, the airline franchise at cowen has been globally respected for decades. we are thrilled you could join us this morning. i want to get to the story of the moment and do sell side 101. your single best buy right now is united airlines. they

one of the downside is biogen, down about 2%.s it cannot yet approve its alzheimer's drug because it does not have the efficacy data that signals it should do so. guy: absolutely. the europeans are taking a very cautious view on that over here. let's get back to the ethics story and the rates -- the fx story and the rates story. thierry wizman, macquarie interest rates and currencies strategist, joining us now. the big question everybody is trying to figure out for next year, certainly when it comes to fx, is this dollar strength that we see this year going to participate that's going to persist into next year? what is your outlook? thierry: our outlook is that the strength and the dollar will persist for at least a few more weeks or months. there's still a lot of legacy issues from 2020, especially the latter part of 2021, that caused the dollar strength that are going to persist. one of them is simply the slow down in the global economy. we think that is going to crimp the economy a little further. that is not going to come out

there's inherent risk in every biotech stock even when you get approval look at biogen, and they come drug and it goes the price and some concerns and it's not effective enough for the price they're charging, but when i take a look at moderna and when i take a look at what's come out of the trials and even the flu vaccine and those results were unjustifiably maligned because it does show superiority to current flu vaccines on the market, i just think that we've got a technology platform here and not a typical biotech company and that technology platform has been proven so will all these drugs in the pipeline and the therapeutics and vaccines be approved i say that's unlikely with any company whether it's in biotech or an auto some don't make it to the market, but nonetheless, as i handicap it, the risk reward is incredible with $15 billion in cash roughly and an annuity will go up, and as they said, pandemic pricing is only in effect during the pandemic once you go to the endemic pricing you'll see a big bump there. >> sure, i just want to make sure that our viewers and investors unde

lauren: breaking news for you, biogen is jumping on a report from the korean economic daily of a potentialout deal by samsung group. the report says the deal could be worth over $42 billion. the stock is up 10% on that report. let's go to lived ya hu for somr big movers today, and you're looking at our pop stocks. >> reporter: hey there, lauren. tracking a lot of movement today. elon musk's stock selling spree seems to have come to an end as the world's richest man has finally exercised -- exorcised the last of his stock options that are set to expire next year. musk sold a further $1 billion worth of stocks to pay for taxes. musk also bought $1.6 million worth in shares of his company on tuesday by exercising tesla options. now, the move comes after musk polled his twitter followers back in november asking if he should sell 10% of his stake in tesla which at the time resulted in a $60 billion hit to the company's market value. musk has now sold a total of $15.6 million -- 15.6 million shares, equaling around $16 billion. he needs to sell 17 million shares in total to reach his target of 1

here's a quick look at lumber up 40% this month and shares of biogen coming back to earth after samsungd not so fast, denying it was in reports to buy it. it's down 8% today >>> now to rahel solomon for our cnbc news update >> here's what's happening at this hour. new york's attorney general claiming a victory in her fight against opioid abuse after a jury found teva pharmaceutical helped fuel opioid addiction across the state teva shares are down more than 4% on the years. >>> nearly a quarter of nba coaches now sidelined by the league's health and safetiy protocols. doc rivers and michael malone the latest to join the list which now includes seven coaches. 120 players are also currently in the protocols kids meantime are being hospitalized with covid in near record numbers as omicron continues to spread. an average of 334 children per day were admitted to hospitals with covid that is a 58% increase from the previous week. >>> and tonight on "the news," omicron's impact on everything from air travel and cruises to working out at a local gym that's tonight at 7:00 eastern kelly, i'll se

which also has good component against obesity, and one for alzheimer which i think is better than biogen. you know i do a lot of work with the american migraine foundation, with the brain foundation these could be potentially multi-billion dollar franchises. we own lilly for the travel trust. while i don't know how positive is will be at the investor meeting, they can be coy the long-term posture is terrific thursday morning, we hear from two amazing companies. accentture and adobe accenture, they know all the players. the stock always trades erratically and then settles down by the end of the day if you don't own it yet, i would wait for the usual buying opportunity before it starts climbing again adobe is a tech name that's so solid, you have my blessing to own it because it's a heck of a lot more tangible than lots of cloud names. however, i'm begging you to not own too many high priced earnings multiple tstocks after the close, fedex reports i have been thinking about this, and as far as i'm concerned, this has got to be the single hardest stock to predict of what it will do next. i

drugmaker biogen said today it's cutting the price of its new alzheimer's treatment in half, to aroundthe first drug to slow the progress of the brain- destroying illness, instead of just managing symptoms. but, it has run into slow sales and a backlash over its high cost. on wall street, the dow jones industrial average lost 433 points to close at 34,932. the nasdaq fell 188 points. the s&p 500 slipped 52. and the white house has a new puppy in residence, named commander. president biden shared a photo on his twitter account today. the dog appears to be a german shepherd and was a gift to biden from his family. still to come on the newshour: tamara keith and amy walter break down the latest political news. closing arguments in the trial of jeffrey epstein associate ghislaine maxwell. doctor francis collins discusses his long career leading the national institutes of health. plus much more. >> woodruff: a stalled agenda in congress and a surge in covid cases. just two issues the white house is struggling with in these final weeks of the year. it's a good time to turn to politics monday

i'll janis down after samsung said they are not buying biogen -- biogen is down after samsung said they are not buying biogen area tesla recalled 500,000 cars. on the upside is carnival. i don't know how many people are looking to get on a cruise. matt: me and paul. we are making our reservation. we are going to go on a cruise. i don't think we have decided yet, but neither one of us has been on a big-time commercial cruise. is that right? paul: i have not been. but i would do it, but maybe not right now. matt: we are going to make reservations, but maybe for 2024. abigail doolittle, thanks very much for catching us up on those markets. it's bring in david jones, b of a global research senior investment strategist. let's get his take on 2022 expectations as we near the end of this year, with 26% gains right now on the s&p 500. what are you looking for in the coming year? david: i guess i have to say i'm one of those more bearish strategists at the moment. we certainly think that returns in the next year are probably going to be low single digits, perhaps even negative. at the broadest l

in japan, after the outcome of drugs with biogen got a negative opinion from the u.n.gs regulator. they will be selling offshore support. the shipping company says it has money from the transaction. orix expects a 2.7 billion dollar gain. covid cases surges to a new record high. 258 million dollars after renegotiating the price, down from the original debt made in preferred better. they have filed f >> we will see about new restrictions. we are discussing the omicron variant. if the government felt that further action had to be taken, we would present that to parliament and it would be for parliament to decide. >> i do not foresee the lockdowns that we had before. i see the potential for stress on our hospital systems. david: coming up, health officials on how they plan to deal with the resurgence in the virus. over the weekend, there has been an omicron variant. there is some concern and may wreak -- delay the recovery for the travel industry. as a international trips are starting to actually -- a lot of international trips are starting to pick up. including like sing

by the way, take a look at milley look autothe biogen.en snubbed and hurt by the ceo. this eli willy drug works. >> we did not nengz eu regulator. we miss you today but enjoy the weekend. >> catch tonight's show. it's going to blow your mind >> okay. that's a tease jim, thanks. >> love you guys >> love you too. >>> let's get to phil with a very special guest hey, phil. >> let's bring in mike royce, president of general motors on a very important morning beginning deliveries of the first electric vehicle on the alityium battery and we have to discuss the announcement of general motors and you're the president, that the ceo of cruise has left the company. and it was a very short announcement all it said is to pursue other opportunities. what can you tell boutsz this? >> as you saw in the company's statement, he's left cruise and we believe it's in great hands with the cofounder and cto so, cruise and gm were really totally aligned on accelerating the autonomous vehicle strategy we outlined in our recent investor day we're leaders in ev tech

. >> look, i have -- with the exception of biogen, which i think was shameful with their alzheimer's take it, i think you're wasting our government's money and i'm aggressive on that i do a lot of work with the brain foundation i will say that the fda, the nih, cdc, have been shameful they've misled us. they have been a major problem in our country which should be open one of them, i think has distinguished themselves i don't think dr. fauci should distinguish himself. i think that the cdc has been terrible and i have to say it because these are organizations that we turn to. i now turn to the government as a farce. president biden was talking about giving 500 million tests out. now, abbott has the ability to produce 50,000 -- 50 million a month. where is he getting this 500 is he going to go to china i don't think we want them i don't know how he's going to do it. and there's absolutely no sketch out of how he's going to do it once again, you know, david, i'm sorry that i'm so negative about these people but i've come to expect more from our country than these people i don't think t

, two is, you know, there is a huge routing of all the companies there is a lot of stocks here at biogenthis i is being most underappreciated are those the two picks? >> yeah. look, i think for the large names, i do think that it has to be the single number one stock for 2022 based on the fact they reported a bunch of great pipeline data for two new drugs. the stock didn't move. i he think as the thesis plays out, we get a bounce i think it is the cleanest and best story for 2022. the i think amgen another one that is totally left out to hang this year. one of the bigger underperformers this year. and that stock islooking good. so i think there is a lot of these oit and stocks that large cap that could bounce back >> yeah. interesting catchup. thank you very much. appreciate it. >> good to see you >> all right up next, kkr's henry mcvey on whether the recent selloff overdone and where he sees buying opportunities right now plus, amc shares swinging higher after spiderman's blockbuster weekend. amc's ceo is weighing in on the impact of the box office boom. det details later on "closinbe."

next, we had spoken again offline about the accelerated pathway and how the biogen drug for alzheimer's obviously addressing the knee which is devastating, but there is a lot of concerns about efficacy, safety and cost. you had mentioned using big data in order to have a quicker answer on drugs such as this. i'd like you to elaborate on that, please. >> we have essentially 300 million-plus americans with electronic health records now. our health data is being used all the time in clinical practice. a lot of my career has been on the issue of how do we use that data, organize it, curate it, and make it useful for research. it sometimes startles people to say the data is good to use in clinical practice but not good for research. and people are like, wait a minute, how can it be that it's good enough for me but not good enough to draw a conclusion? i think we're down the road now to having a functional system. but i also want to assure people i'm not talking about willy-nilly wellness of data, i'm talking about frequent use of randomization. if we look at the u.k., they organized as a cou

imagine it would have been nice going into the biogen conference that tuned in to the superspreadinghat rubric wasn't well adapted for the situation that ended up unfolding that you needed something that would work fast and instead what happened people waited in lines for pcr test that is didn't come back for days at a time. >> in a statement the fda writes, quote, unfortunately, many submissions the fda has received for home tests include incomplete or poor data. it is the fda's responsibility to protect the public health by declining to authorize poorly performing tests or those without data. by balancing speed with safety we have taken numerous actions to accurate and reliable at-home tests. mike barnicle, you have the next question. >> yes. specifically what tests were destroyed? what were the tests aimed at achieving? >> that's not my reporting. that's "the new york times" reporting. abbott labs said later complete tests weren't destroyed but they did shut down a factory and the reason for that is over the summer of 2021 we had the vaccines. people were pretty certain were work

stuart: biogen, what is the movement there?000. that would be good news. you have more access. more of a fordability. yet now, you have a panel of experts now asking the fda to pull it from the market. they don't like the side-effects. stuart: pull it off the market completely. they cut the price in half, that is not good enough. take it off the markets say the experts. surprised at that. what else we got? citric system, i know that company. there must be a takeover there. lauren: number one on s&p 500. a report that elliot investment management and considering a joint bid for citric that makes work place software. we saw a lot of software deals, oracle an cerner, oracle buying them $28 million. stuart: this one is for you. i find it fascinating. a classic 195porsche, 356 it is called, it completed a an arctic road trip. you tell me nor about that? lauren: the 65-year-old driver didn't preserve her 65-year-old car. she converted it into a snowmobile. look at that, modified with skis on the front, tracks on the back. she was tac

jd off right now about 2%, you are look to biogen is off 2% as well it's moving down as we speak so a to put it >> making headlines this morning. oracle is trying to make an agreement to buy cerner. in healthcare, they're up sharply this morning, 19%. >>> fed-ex revenue jumping 14% higher shipping rates reinstating the profit target. it's launching a if you $35 billion stock buyback. johnson&johnson shares are trading lower. they say the occurrence of a rare blood clotting disorder is higher than previously detected. as a result, the cdc is now recommending the pfizer and moderna vaccines over johnson&johnson's jab. here's what dr. fauci told us in the last hour. >> the shift and the change that occurred yesterday regarding a recommendation of a preference for the mrna over j&j really was nailed down by the very recent data that there are more of these adverse events than was originally thought still the cdc was saying particularly taking into account the safety data with regard to adverse events, if you had the choice favor the mrna. >> we will talk about this and other issues relate

exact sciences, merck, biotech, biogen, teladoc. teladoc had a horrible year. i will be focusing on those. not all of them. you have to do your fundamental research. but i think some of those could be very attractive. matt: why did some of those underperformed? what is your best guess as to why investors did not value them as highly as they did tech stocks? cate: there are a couple of things going on. in the case of something like exact sciences, the sales people could not get in front of the doctors because of covid. there are other cases where procedures could not get done because of covid. in the case of something like teladoc, teladoc had done so well because of telemedicine that there was this perception that things were reopening. teladoc just fell completely out of favor. united states physical therapy, this was one where procedures have not gone down. they provide -- excuse me, they provide physical therapy services, and the numbers were not down. they were up 18% over 2019, yet the stock did not perform well. so i think those are some of the names you